Summary.-The effect of simultaneous whole-body heat (45 min 41°C) on cyclophosphamide (CTX) and BCNU toxicity to normal mouse marrow stem cells and to the RIF-1 tumour in C3H/He mice has been studied. Marrow stem-cell survival was assayed by the spleen-colony technique at both 2 and 24 h after treatment, and also by following peripheral WBC count during the weeks after treatment. Heat potentiation of CTX toxicity to marrow stem cells was similar at both times and 24 h after treatment heat was dose-modifying with a DMF of 2-0. The heat potentiation of BCNU toxicity to stem cells was much greater at 24 h than at 2 h, and at 24 h had a DMF of 2-1. Peripheral WBC counts supported the results from 24 h assay for both drugs. RIF-1 tumour response was assayed by clonogenic cell survival measured 24 h after treatment, and by growth delay. For clonogenic tumour-cell survival after CTX, heated and unheated curves were parallel at doses above 75 mg/kg, yielding DMFs varying between 1-9 and 1-4 according to dose. DMFs for BCNU were also dosedependent, lying between 2.0 and 1 6, the RIF-1 tumour being much less sensitive to BCNU than to CTX. Growth-delay data agreed with clonogenic cell survival. Therapeutic ratios for the combination of heat with CTX or BCNU fell in the range 0-91-0-69, according to dose, i.e. no gain or even therapeutic loss under the conditions of this study.
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THE POTENTIATING EFFECT of heat on the in vivo tumoricidal activity of a number of cytotoxic drugs including CTX, BCNU, Bleomycin and Adriamycin is now well established (Overgaard, 1976; Hahn, 1978; Twentyman et al., 1978; Marmor, 1979) . So far there have been few normaltissue studies on such combinations, though we have previously reported work on skin (Honess & Bleehen, 1980) . However, marrow may be a more critical normal tissue, in that a limiting toxicity of two of the drugs mentioned above (CTX and BCNU) is to the marrow when each is administered clinically as a single agent. Sabio et al. (1981) have reported in mice that hyperthermia alone (41.5-44 5°C) decreases the number of stem cells available for proliferation and also that the proliferative potential of surviving cells is decreased. Symonds etal. (1981) , studying the effects of in vitro hyperthermia (41-44°C) on stem cell and L1210 leukaemia cell survival, report similar slopes for survival curves for both cell types, but a greater susceptibility of L1210 cells to heat when in the presence of normal marrow. Chrisman & Baumgartner (1980) have demonstrated highly significant effects of heat, CTX (40 mg/kg) and of the interaction of heat and CTX on the incidence of micronucleated polychromatic erythrocytes in the marrow of ICR mice. Rose et al. (1979) have investigated the effect of whole-body hyperthermia as an adjunct to a variety of chemotherapeutic agents in several mouse tumour systems, using death as the endpoint, and failed to demonstrate any reproductible or stubstantial enhancement of the chemotherapy. In the work described here we have studied the effects of the combination of heat with CTX or BCNU on the femoral marrow of normal C3H/He mice, using the spleen-colony assay of Till & MeCCulloch (1961) Both drugs were diluted in Hanks' balanced salt solution and injected i.p. When combined with heat treatment, drugs were always given at the start of heating.
Hyperthermia
Unanaesthetized, unrestrained mice were given whole-body hyperthermia by enclosing them in a wire-mesh cage (allowing maximum ventilation) placed in an incubator at 44°C. The cage was situated under a fan which ensured brisk air circulation, and fresh air was pumped into the incubator at a rate of 10 1/min, which allowed a complete change of air every 15 min. It was found that these two features markedly reduced animals, susceptibility to heat stroke at this treatment temperature. A maximum of 8 mice were treated per session.
Independent measurements of rectal temperature in mice restrained sufficiently to allow a rectal probe to be kept in place, while still allowing free sweating, showed that the rectal temperature reached 41 + 0 2°C within 5-10 min of the start of heating, and was maintained throughout treatment. Intratumour measurements in these animals showed that the temperature in the centre of the tumour was always closely associated with the rectal temperature and within + 0 2°C of it. The temperature at the very surface of the tumour, however, tended to be higher than the rectal temperature, and approached that of the skin of the animal, which was at the higher incubator temperature.
A standard heat treatment of 45 min at 41°C was used in all the experiments reported below, which entailed 50 min total time in the incubator. A BAT-8 digital thermometer (Bailey Instruments Inc.) was used to monitor rectal and intratumour temperatures and incubator air temperatures, the air probe being carefully shielded from the fan.
Normal-tissue end-points
Marrow stem-cell survival.-This was measured by the spleen colony (CFU-S) assay of Till & McCulloch (1961) . Groups of 10-15 recipient mice were lethally irradiated with 8-25 Gy of 60Co y-rays the evening before receiving i.v. a marrow-cell suspension, prepared from at least 2 control or treated donor mice by killing the animal by cervical dislocation, dissecting out the femurs, cutting off the distal end of the femur with scissors and making a hole in the proximal end between the condyles with a 25-gauge needle and flushing out the contents into a glass universal container with 1 ml of HBSS. The femur was flushed through twice more with 1 ml of HBSS and this 3 ml suspension was then syringed repeatedly to obtain a singlecell suspension which was kept on ice until injection into the recipients. It was found that this method of harvesting yielded 99% + of the total obtained by many subsequent flushings. A sample of the suspension was then diluted 1:1 or more (according to cell count) with 2% glacial acetic acid in distilled water. This lysed the red blood cells and allowed nucleated cells to be counted in a haemacytometer. Appropriate dilutions of marrow-cell suspension were made in HBSS; so that each recipient mouse received 0-2 ml given i.v. into the tail vein. Injections were performed without anaesthaesia, and were facilitated by dipping the tail in hot water for a few seconds to dilate the vein before injection, then in ice water afterwards to encourage vasoconstriction and reduce the likelihood of bleeding.
Marrow recipients were killed 7-8 days after i.v. injection and the spleens were removed and fixed in Bouin's fluid, which allowed the colonies on the surface of the spleen to be clearly seen as yellow nodules against a dark background. Colonies were counted under a low-power stereomicroscope.
In this system it was found that for control, untreated marrow, an inoculum of 105 nucleated cells produced 10-15 colonies per spleen. It was shown that the number of colonies depended linearly on the number of cells injected, up to a colony count of 25-30. Where there were 30+ colonies it was impossible to make an accurate count because of crowding. Cell inocula were therefore adjusted to give colony counts of 5-20 per spleen. Drug doses were chosen to matclh the stemcell survival experiments -where possible, but only lower doses of BCNU were compatible with survival for the length of the experiment.
Tuwour
The tumour used in this, work -was the RIF-I tumour wNhich has been previously described by Twentyman et al. (1980) . It was grown i.m. in the leg by injection of 105 cells from culture. Animals wN-ith tumour,s were treated when the tumours reached a size of 300-600 mm3, usually Day 9-10 after inoculation. tumour volume being estimated from a calibration curve of tumour weight (propor- tional to tumour volume) as a function of the product of two mutually perpendicular leg diameters (TwNentyman et al., 1979 
RESULTS
.Normal tissue CFU-S. The drop in yield of nucleated cells per femur 24 h after drug treatment is shown in Fig. 1 . For CTX, the drop appeared to be dose-dependent, with a 300o yield at 200 mg/kg in unheated animals, heated femur yields being consistently lower. For BCNU, the unheated vield was about 5000 over the range of Fig. 3 , and the parameters for these curves are also given in Table I 1-2+0-9 10 3-8+2-6 7* 0-8+0 9 10 2-0+ 1 0 10 the 2h stem-cell dose-response curve for unheated CTX-treated animals 24 h after treatment is in accordance with the observations of Hellman & Grate (1971) , who assayed at 3 and 24 h after treatment in C3H/Hej mice. The effect of combining CTX with heat appears similar at both early and late assays, in that the shoulder on the 2h dose-response curve is maintained in heated animals ( Fig. 3 ) and the slopes of the exponential parts of the 2h response curves do not differ from the slopes of the corresponding 24h curves (Table I) (Valeriote et al., 1968) and in vitro assay (Brown & Carbone, 1971 ) and this would perhaps support the view that the 24h assay is the more useful. The fact that the peripheral WBC counts, being a measure of the end-product of stem cell killing, appear to agree more closely with the 24h stem-cell assay than with the 2h assay for both drugs (see Results) again argues that the 24h stem-cell assay data are the more relevant.
As already stated, 24 h after treatment is the optimum time for a reliable estimate of clonogenic tumour-cell survival, in that all or most repair of PLD is complete, but there has been little time for proliferation of clonogenic surviving cells. The agreement between the tumour-regrowth data and the clonogenic assay supports the validity of the 24h clonogenic assay. Hence the comparison of 24h stem-cell survival with 24h clonogenic tumour-cell survival is likely to give realistic estimates of TR for the combination of heat with the drugs tested. These estimates are most discouraging from a therapeutic viewpoint, as they indicate variation from no therapeutic gain to a considerable therapeutic loss, according to the dose of drug (Table  IV) . However, these studies only involve combinations where drug is given at the start of heating, and it is possible that the time scale of heat potentiation of drug toxicity may be substantially different for tumour and normal tissues, thus allowing a therapeutic advantage. Such an effect has been shown for the combination of waterbath heating and X-rays, using skin desquamation as the normal-tissue endpoint (Hill & Denekamp, 1979) .
It is interesting that very similar TRs were obtained for two drugs, CTX being very active against the RIF-l tumour and BCNU relatively inactive against this tumour, even at very high doses. Despite the insensitivity of RIF-1 to BCNU, the toxicity observed was potentiated to about the same degree by the heat as was that of CTX, though the data are not as clear as those for CTX, being almost all within one decade of killing. This led to similar TRs, since the sensitivity of marrow stem cells was similar to both drugs over the dose ranges used. It would be interesting to investigate heat potentiation of the BCNU effect against a BCNUsensitive tumour in the same strain of mouse, which we have not yet been able to do.
The lack of therapeutic advantage seen from this work is perhaps all the more discouraging from a clinical point of view because the temperature and time for which it is maintained (41°C for 45 min) constitute such a mild treatment. It is true that mice are not the ideal model animals for whole-body hyperthermia, being highly susceptible to heat stroke, but it seems reasonable to assume that, if animals do not succumb to heat stroke, the reactions of their haemopoietic systems might be typically mammalian. Much higher temperatures than 4 l0C are currently being tried for longer periods of local hyperthermia in clinical studies and, as already mentioned, it has been suggested that mild whole-body hyperthermia (at up to 41°C) might be deliberately used in conjunction with local heating to reduce the problem of blood cooling. This problem of blood cooling remains despite the recent improvements in techniques of localizing administered heat. Our results suggest that any attempt to combine agents such as CTX or BCNU with such heating methods would be most unwise, and thus essentially agree with the findings of Rose et al. (1979) . These workers used an incubator heating method, but unfortunately their heat doses (quoted as > 415°C for 20 min and > 41°C for 30 min) which resulted from accumulation of body heat in an incubator at 387°C cannot be compared with ours. This is because the "temperature measurement" mice were anaesthetized with pentobarbitone, while the experimental mice were not. It is now known that pentobarbitone anaesthesia abolishes the animal's temperature-regulation mechanism, so the temperature of the monitored mice is unlikely to represent that of the experimental mice, and it is most likely that the unanaesthetized mice at a much lower temperature.
The work presented in this paper indicates that the simultaneous combination of heat and CTX or BCNU leads to no therapeutic gain, and under some conditions to therapeutic loss, the therapeutic ratios being estimated by comparing tumour toxicity and marrow toxicity.
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